HK1205931A1 - Pharmaceutical formulation for reducing frequency of urination and method of use thereof - Google Patents

Pharmaceutical formulation for reducing frequency of urination and method of use thereof Download PDF

Info

Publication number
HK1205931A1
HK1205931A1 HK15106439.9A HK15106439A HK1205931A1 HK 1205931 A1 HK1205931 A1 HK 1205931A1 HK 15106439 A HK15106439 A HK 15106439A HK 1205931 A1 HK1205931 A1 HK 1205931A1
Authority
HK
Hong Kong
Prior art keywords
release
formulated
analgesic
pharmaceutical composition
agents
Prior art date
Application number
HK15106439.9A
Other languages
English (en)
Chinese (zh)
Inventor
．迪爾 大衛．
大卫．A．迪尔
Original Assignee
韦尔斯利医药有限公司
大卫．A．迪尔
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/560,665 external-priority patent/US8445011B2/en
Priority claimed from US13/800,761 external-priority patent/US20130196012A1/en
Priority claimed from US13/847,940 external-priority patent/US8703184B2/en
Application filed by 韦尔斯利医药有限公司, 大卫．A．迪尔 filed Critical 韦尔斯利医药有限公司
Publication of HK1205931A1 publication Critical patent/HK1205931A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15106439.9A 2012-07-27 2013-06-28 Pharmaceutical formulation for reducing frequency of urination and method of use thereof HK1205931A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13/560,665 2012-07-27
US13/560,665 US8445011B2 (en) 2010-07-08 2012-07-27 Delayed-release formulation for reducing the frequency of urination and method of use thereof
US13/800,761 US20130196012A1 (en) 2010-11-30 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/800,761 2013-03-13
US13/847,940 US8703184B2 (en) 2010-07-08 2013-03-20 Delayed-release formulation for reducing the frequency of urination and method of use thereof
US13/847,940 2013-03-20
PCT/US2013/048616 WO2014018222A1 (en) 2012-07-27 2013-06-28 Pharmaceutical formulation for reducing frequency of urination and method of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK18105893.7A Division HK1246203A1 (zh) 2012-07-27 2015-07-06 用於缓解尿频的药物制剂及其使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK18105893.7A Addition HK1246203A1 (zh) 2012-07-27 2015-07-06 用於缓解尿频的药物制剂及其使用方法

Publications (1)

Publication Number Publication Date
HK1205931A1 true HK1205931A1 (en) 2015-12-31

Family

ID=49997724

Family Applications (4)

Application Number Title Priority Date Filing Date
HK15106439.9A HK1205931A1 (en) 2012-07-27 2013-06-28 Pharmaceutical formulation for reducing frequency of urination and method of use thereof
HK15106440.6A HK1205932A1 (en) 2012-07-27 2013-06-28 Pharmaceutical formulation for bedwetting and method of use thereof
HK18110004.3A HK1250628A1 (zh) 2012-07-27 2015-07-06 用於遗尿的药物制剂及其使用方法
HK18105893.7A HK1246203A1 (zh) 2012-07-27 2015-07-06 用於缓解尿频的药物制剂及其使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK15106440.6A HK1205932A1 (en) 2012-07-27 2013-06-28 Pharmaceutical formulation for bedwetting and method of use thereof
HK18110004.3A HK1250628A1 (zh) 2012-07-27 2015-07-06 用於遗尿的药物制剂及其使用方法
HK18105893.7A HK1246203A1 (zh) 2012-07-27 2015-07-06 用於缓解尿频的药物制剂及其使用方法

Country Status (16)

Country Link
US (3) US20160022615A1 (enExample)
EP (3) EP2844241A4 (enExample)
JP (4) JP2015522658A (enExample)
KR (2) KR20150048740A (enExample)
CN (4) CN107335057A (enExample)
AU (3) AU2013293488B2 (enExample)
BR (2) BR112014031306A2 (enExample)
CA (2) CA2875818A1 (enExample)
HK (4) HK1205931A1 (enExample)
IL (3) IL236028A0 (enExample)
MX (2) MX2015001190A (enExample)
MY (1) MY171526A (enExample)
RU (3) RU2019101864A (enExample)
SG (2) SG11201500578VA (enExample)
WO (2) WO2014018222A1 (enExample)
ZA (2) ZA201408993B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201805810PA (en) * 2015-09-01 2018-08-30 Wellesley Pharmaceuticals Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
EP3355877A4 (en) * 2015-09-30 2019-05-15 Wellesley Pharmaceuticals, LLC COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF
KR20180066112A (ko) * 2015-09-30 2018-06-18 웰즐리 파마슈티컬스 엘엘씨 배뇨 빈도 감소용 조성물, 제조 방법 및 용도
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
WO2019094989A1 (en) * 2017-11-07 2019-05-16 Poviva Tea, Llc Food and beverage compositions comprising pde5 inhibitors
JP7787190B2 (ja) 2021-02-23 2025-12-16 大塚製薬株式会社 センタナファジン製剤ならびにその製造および使用方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69927708T2 (de) * 1998-12-23 2006-07-06 Alza Corp., Mountain View Dosierungsformen, die poröse partikel enthalten
AU7360000A (en) * 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating prostate disorders
MXPA03001717A (es) * 2000-08-30 2003-09-22 Lilly Icos Llc METODO PARA EL TRATAMIENTO DE LA MIGRAnA.
WO2003029199A1 (en) * 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Benzene derivatives, process for preparing the same and use thereof
BR0307772A (pt) * 2002-02-19 2004-12-07 Pharmacia Corp Uso de inibidores da ciclooxigenase e de agentes antimuscarìnicos para o tratamento da incontinência
WO2004043365A2 (en) * 2002-11-06 2004-05-27 Azaya Therapeutics, Inc. Method for treatment of premature ejaculation in humans
CA2646729A1 (en) * 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methods and compositions for the treatment of urinary incontinence
EP1741444A1 (en) * 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2007083323A2 (en) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
WO2007113243A2 (en) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
CA2988753A1 (en) * 2007-08-06 2009-02-12 Serenity Pharmaceuticals, Llc Methods and devices for desmopressin drug delivery
CN101664555A (zh) * 2008-09-02 2010-03-10 许洁 用于治疗泌尿生殖系统感染性疾病的联合药物组合物
CN102028693A (zh) * 2009-09-30 2011-04-27 梁超峰 含有5-型磷酸二酯酶抑制剂的直肠给药组合物
US9260424B2 (en) * 2009-10-26 2016-02-16 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
US20120141554A1 (en) * 2010-07-08 2012-06-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction
US8236857B2 (en) * 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US8236856B2 (en) * 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
MX2015001190A (es) 2015-05-07
KR20150048741A (ko) 2015-05-07
AU2013293488A2 (en) 2015-02-26
RU2015106762A (ru) 2016-09-20
SG11201500578VA (en) 2015-03-30
AU2013293488B2 (en) 2018-05-17
IL261232A (en) 2018-10-31
ZA201500459B (en) 2016-09-28
HK1205932A1 (en) 2015-12-31
MY171526A (en) 2019-10-16
WO2014018223A1 (en) 2014-01-30
EP2877179A4 (en) 2016-03-02
US20170100351A1 (en) 2017-04-13
AU2018208765A1 (en) 2018-08-16
CA2875818A1 (en) 2014-01-30
JP2015522659A (ja) 2015-08-06
EP2877179A1 (en) 2015-06-03
AU2013293488A1 (en) 2015-02-19
HK1250628A1 (zh) 2019-01-11
MX2015001188A (es) 2015-05-07
WO2014018222A1 (en) 2014-01-30
CN107661326A (zh) 2018-02-06
US20160022615A1 (en) 2016-01-28
JP2018127482A (ja) 2018-08-16
EP2844241A1 (en) 2015-03-11
ZA201408993B (en) 2016-09-28
AU2013293489B2 (en) 2017-09-07
US20180344674A1 (en) 2018-12-06
BR112015001627A2 (pt) 2017-07-04
CN107335057A (zh) 2017-11-10
IL236028A0 (en) 2015-01-29
CA2879640A1 (en) 2014-01-03
EP3527204A1 (en) 2019-08-21
HK1246203A1 (zh) 2018-09-07
RU2019101864A (ru) 2019-03-11
CN104470522A (zh) 2015-03-25
IL236622A0 (en) 2015-02-26
KR20150048740A (ko) 2015-05-07
SG11201500601QA (en) 2015-04-29
EP2844241A4 (en) 2015-04-29
JP2015522658A (ja) 2015-08-06
JP2018039831A (ja) 2018-03-15
CN104540505A (zh) 2015-04-22
BR112014031306A2 (pt) 2017-06-27
AU2013293489A1 (en) 2015-03-12
RU2015106672A (ru) 2016-09-20

Similar Documents

Publication Publication Date Title
US20130196012A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
AU2013235518B2 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
AU2012363789A2 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
AU2018208765A1 (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20170319579A1 (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
HK1248549A1 (zh) 用於缓解尿频的延长释放制剂及其使用方法
US20170100413A1 (en) Composition for reducing the frequency of urination, method of making and use thereof
EP2612663A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
TWI587879B (zh) 用於減少排尿頻率的延長釋放製劑及其使用方法
HK1257452A1 (zh) 缓解尿频的组合物，其制造方法和应用
HK1259770A1 (en) Composition for reducing the frequency of urination, method of making and use thereof
HK1259497A1 (en) Composition for reducing the frequency of urination, method of making and use thereof
HK1187241A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof